Rxiv July News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rxiv july. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rxiv July Today - Breaking & Trending Today
Amyloids Fibrillize, or Stay Solo, Based on Liaisons with Similar Proteins alzforum.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzforum.org Daily Mail and Mail on Sunday newspapers.
Rigel Reports First Quarter 2021 Financial Results and Provides Business Update - Reported positive topline results of fostamatinib in Phase 2 clinical trial in hospitalized patients with COVID-19 - Net product sales of $12.4 million and total revenues of $81.0 million - Received upfront cash payment of $125 million from Eli Lilly for the exclusive license agreement for Rigel s RIP1 inhibitor program - Conference call and webcast today at 4:30PM Eastern Time News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALISSE ....
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million - Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel s RIP1 inhibitor program - Launched a Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients - Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021 - Conference call and webcast today at 4:30PM Eastern Time News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2020, including sales of TAVALISSE ....
January 29, 2021 2:45pm EST Study has the potential to facilitate a filing for Emergency Use Authorization (EUA) SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 / / Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE ® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP). ....
Share this article Share this article SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE ® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP). We are grateful to receive this funding from the DOD and for their demonstrated commitment towards finding safe and effective treatments for COVID-19 patients, said Raul Rodriguez, Rigel s president and CEO. These additional resources will contribute significantly to the advancement of our P ....